Projects per year
Projects
- 6 Active
Search results
-
Active
An open-label, non-randomized extension study to evaluate the long-term efficacy, safety and tolerability of iptacopan (LNP023) in C3 glomerulopathy or idiopathic immune-complex- membranoproliferative glomerulonephritis
Klomjit, N. (PI)
NOVARTIS PHARMACEUTICALS CORPORATION
4/15/25 → 4/14/36
Project: Research project
-
An open-label study to assess the efficacy and safety of extended TARPEYO? (delayed-release budesonide capsules) treatment in adult patients with...
Klomjit, N. (PI)
4/15/25 → 4/14/36
Project: Research project
-
Q32 Bio Inc. Primary Funding Source:2. Proposal Title: A Phase 2 Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Clinical Activity ofADX-097 Administered Subcutaneously in Male and Female Participants Aged 18 Years or Older With
Klomjit, N. (PI)
11/3/24 → 3/31/34
Project: Research project
-
A multicenter, single-arm, open label trial to evaluate efficacy and safety of oral, twice daily LNP023 inadult atypical hemolytic uremic syndrome (aHUS) patients who are naive to complement inhibitor therapy
Klomjit, N. (PI)
NOVARTIS PHARMACEUTICALS CORPORATION
3/1/24 → 2/28/27
Project: Research project
-
multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacyand safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferativeglomerulonephritis (IC-MPGN).
Klomjit, N. (PI)
NOVARTIS PHARMACEUTICALS CORPORATION
7/11/23 → 8/19/28
Project: Research project